Zetonna Patent Expiration

Zetonna is a drug owned by Covis Pharma Gmbh. It is protected by 9 US drug patents filed in 2013. Out of these, 1 drug patents are active and 8 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 01, 2028. Details of Zetonna's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(3 years from now)

Active
US6264923 Medicinal aerosol formulation of ciclesonide and related compounds
May, 2018

(6 years ago)

Expired
US6120752 Medicinal aerosol products containing formulations of ciclesonide and related steroids
May, 2018

(6 years ago)

Expired
US5482934 Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
Oct, 2017

(6 years ago)

Expired
US6006745 Device for delivering an aerosol
Dec, 2016

(7 years ago)

Expired
US5775321 Seal configuration for aerosol canister
Jul, 2015

(9 years ago)

Expired
US5683677 Medicinal aerosol formulations
Nov, 2014

(9 years ago)

Expired
US5605674 Medicinal aerosol formulations
Feb, 2014

(10 years ago)

Expired
US6036942 Seal configuration for aerosol canister
Apr, 2013

(11 years ago)

Expired


FDA has granted several exclusivities to Zetonna. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zetonna, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zetonna.

Exclusivity Information

Zetonna holds 1 exclusivities. All of its exclusivities have expired in 2015. Details of Zetonna's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 20, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Zetonna's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Zetonna's generic, the next section provides detailed information on ongoing and past EP oppositions related to Zetonna patents.

Zetonna's Oppositions Filed in EPO

Zetonna has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 25, 2014, by Generics [Uk] Ltd (Trading As Mylan). This opposition was filed on patent number EP04766791A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP04766791A Sep, 2014 Generics [UK] Ltd (trading as Mylan) Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Zetonna is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zetonna's family patents as well as insights into ongoing legal events on those patents.

Zetonna's Family Patents

Zetonna has patent protection in a total of 12 countries. It's US patent count contributes only to 31.6% of its total global patent coverage. Click below to unlock the full patent family tree for Zetonna.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Zetonna's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 01, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zetonna Generics:

There are no approved generic versions for Zetonna as of now.

Alternative Brands for Zetonna

Zetonna which is used for treating inflammatory conditions, seasonal and perennial allergic rhinitis in adults and adolescents, and respiratory diseases in children., has several other brand drugs in the same treatment category and using the same active ingredient (Ciclesonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Covis
Alvesco

(uses Ciclesonide)

Used for treating asthma and inflammatory conditions in adolescents and adults.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ciclesonide. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Covis
Omnaris






About Zetonna

Zetonna is a drug owned by Covis Pharma Gmbh. It is used for treating inflammatory conditions, seasonal and perennial allergic rhinitis in adults and adolescents, and respiratory diseases in children. Zetonna uses Ciclesonide as an active ingredient. Zetonna was launched by Covis in 2012.

Approval Date:

Zetonna was approved by FDA for market use on 20 January, 2012.

Active Ingredient:

Zetonna uses Ciclesonide as the active ingredient. Check out other Drugs and Companies using Ciclesonide ingredient

Treatment:

Zetonna is used for treating inflammatory conditions, seasonal and perennial allergic rhinitis in adults and adolescents, and respiratory diseases in children.

Dosage:

Zetonna is available in aerosol, metered form for nasal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.037MG/INH AEROSOL, METERED Discontinued NASAL